Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma

被引:13
|
作者
Zhuang, Hongkai [1 ,2 ]
Chen, Bo [3 ]
Tang, Chenwei [1 ,2 ]
Chen, Xinming [4 ]
Tan, Wenliang [1 ,2 ]
Yang, Lei [1 ,2 ]
Xie, Zhiqin [1 ,2 ]
Ma, Xiaowu [1 ,2 ]
Wang, Qingbin [1 ,2 ]
Zhang, Chuanzhao [5 ]
Shang, Changzhen [1 ,2 ]
Chen, Yajin [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China
[3] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Shenshan Med Hosp, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Shanwei, Peoples R China
[5] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Gen Surg, Guangzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
HCC; LSM; prognosis; ICB; immunosuppression; CD8(+) T cell; ANTITUMOR IMMUNITY; THERAPY; REVEAL; CANCER; CELLS; BINDS;
D O I
10.3389/fonc.2022.871771
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundSmith-like (LSM) family members play critical roles in multiple oncologic processes in several types of malignancies. The study on LSM family members of HCC might provide new insights into the tumorigenesis and therapeutic strategies of HCC. MethodsThe clinical significance and oncologic biological functions of LSM family members were assessed through multiple bioinformatics methods and in vitro studies. The potential correlation between LSM family members and tumor immunity was also investigated using single sample gene set enrichment analysis (ssGSEA) and the ESTIMATE algorithm. ResultsLSM family member overexpression in HCC was significantly correlated with poor clinical outcomes such as higher TNM stage, advanced histologic grade, and worse prognosis. A risk score system based on LSM5, LSM10, LSM12, and LSM14B showed a reliable predictive ability for OS of HCC patients. Functional enrichment analysis demonstrated that LSM family members overexpressed were all involved in cell cycle related biological processes. Besides, LSM12, LSM14A, and LSM14B were found to be significantly associated with PI3K-Akt-mTOR and T cell receptor signaling pathways. Tumors with LSM12, LSM14A, and LSM14B overexpression exhibited lower infiltration of activated CD8(+) T cells with declined cytolytic activity and immune score, but increased infiltration of Th2 cells and Th2/Th1. LSM12, LSM14A, and LSM14B overexpression is also associated with higher tumor-related immune checkpoints (e.g., PD-L1, B7-H3, and PVR) expression and increased therapeutic insensitivity to immune checkpoint blockade (ICB). Moreover, the knockdown of LSM12, LSM14A, and LSM14B significantly inhibited the proliferation and invasion of HCC cells. ConclusionThis study systematically investigated the expression pattern and biological values of LSM family members in HCC and identified LSM family members as novel therapeutic targets in HCC.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma
    Yang, Bo
    Zhao, Yonghui
    Wang, Lan
    Zhao, Yuanyuan
    Wei, Lai
    Chen, Dong
    Chen, Zhishui
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer
    Liu, Qianhui
    Lian, Qinghai
    Song, Yingqiu
    Yang, Shangbin
    Jia, Changchang
    Fang, Jiafeng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Identification of novel diagnostic and prognostic biomarkers for hepatocellular carcinoma
    Wang, Fang
    Dong, Junqiang
    Zhang, Yonggao
    Yue, Songwei
    Guo, Hua
    Liang, Pan
    Zhou, Yue
    Wei, Yijuan
    Zhai, Wenlong
    Gao, Jianbo
    ONCOLOGY REPORTS, 2020, 43 (01) : 87 - 98
  • [4] Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma
    Hu, Xiaoyi
    Bao, Mingyang
    Huang, Jiacheng
    Zhou, Lin
    Zheng, Shusen
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [5] Identification of novel biomarkers for hepatocellular carcinoma using transcriptome analysis
    Xia, Qianlin
    Li, Zehuan
    Zheng, Jianghua
    Zhang, Xu
    Di, Yang
    Ding, Jin
    Yu, Die
    Yan, Li
    Shen, Longqiang
    Yan, Dong
    Jia, Ning
    Chen, Weiping
    Feng, Yanling
    Wang, Jin
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 4851 - 4863
  • [6] Novel biomarkers in hepatocellular carcinoma
    De Stefano, Felice
    Chacon, Eduardo
    Turcios, Lilia
    Marti, Francesc
    Gedaly, Roberto
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (11) : 1115 - 1123
  • [7] Identification of novel microRNAs: Biomarkers for pathogenesis of hepatocellular carcinoma in mice model
    Priya, Shivani
    Kma, Lakhon
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2025, 41
  • [8] Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis
    Kamiyama, Toshiya
    Yokoo, Hideki
    Furukawa, Jun-Ichi
    Kurogochi, Masaki
    Togashi, Tomoaki
    Miura, Nobuaki
    Nakanishi, Kazuaki
    Kamachi, Hirofumi
    Kakisaka, Tatsuhiko
    Tsuruga, Yosuke
    Fujiyoshi, Masato
    Taketomi, Akinobu
    Nishimura, Shin-Ichiro
    Todo, Satoru
    HEPATOLOGY, 2013, 57 (06) : 2314 - 2325
  • [9] Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC)
    Sarker, Debashis
    Pedicona, Federico
    Zen, Yoh
    Borek, Weronika E.
    Khorsandi, Shirin Elizabeth
    Christopher, Josie
    Karampera, Christina
    Dowe, Thomas
    Heaton, Nigel
    Cutillas, Pedro Rodriguez
    Dokal, Arran David
    Britton, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Identification and verification of novel ferroptosis biomarkers predicts the prognosis of hepatocellular carcinoma
    Wu, Siqian
    Liu, Meiliang
    Xiao, Suyang
    Lai, Mingshuang
    Wei, Liling
    Li, Deyuan
    Wang, Lijun
    Yin, Fuqiang
    Zeng, Xiaoyun
    GENOMICS, 2023, 115 (06)